BiotechTube
Home/Telo Therapeutics/Glenn Michelson, MD
GM

Glenn Michelson, MD

Clinical Development

Telo Therapeutics

Therapeutic Areas

Oncology

Telo Therapeutics Pipeline

DrugIndicationPhase
TSM74Solid and Hematological Cancers (via XPO1 degradation)Pre-clinical

Leadership Team at Telo Therapeutics

RB
Robert Bell, Ph.D.
CEO & Co-Founder
MD
Michael D Taylor, Ph.D.
Executive Chairman
KW
Katherine Widdowson, Ph.D.
Preclinical Development
MP
Mike Placke, Ph.D.
Non-clinical Safety
VE
Vassil Elitzin, Ph.D.
CMC
View full Telo Therapeutics profile